Clinical evidence dossier
Metformin
Fasting blood sugar (FBS)
Evidence signal
Authoritative evidence signal
strong
This is an authoritative evidence signal supplied by Clinical Reference. It is not a formal clinical grade, treatment recommendation, or pooled effect estimate.
Evidence snapshot
- Authoritative support records
- 3
- Supporting studies available for review
- 3
- Randomized trials
- 2
- Reported effects
- 6
Clinical conclusion
Metformin shows a moderate positive evidence signal for improving Fasting blood sugar (FBS) across the studied comparisons.
The conclusion and evidence-signal classification are distinct authoritative fields and are reproduced as published.
Observed effects
Evidence composition
- Non-randomized studies
- 0
- Other designs
- 0
- Unresolved designs
- 1
- Magnitude-eligible effects
- 0
Consistency
Authoritative consistency classification
mostly_consistent
- Positive
- 2
- No effect
- 1
- Mixed
- 0
- Negative
- 0
Population and applicability
Structured population data were available for 3 of 3 supporting studies. 3 studies described participants with type 2 diabetes. 3 studies described adult participants.
This population information refers to the materialized supporting studies available for review. Omitted support records remain part of the authoritative support accounting and are available through the audit experience.
View reported population descriptions
These descriptions are reported across the supporting studies; they are not a single synthesized population.
- Adults diagnosed with type 2 diabetes mellitus.
- Patients currently on metformin therapy.
- Adults diagnosed with type 2 diabetes.
- Patients with non-alcoholic fatty liver disease (NAFLD).
- Adults newly diagnosed with Type 2 diabetes.
- Patients seeking pharmacological management for diabetes.
Limitations
- 1 relevant study has unresolved authoritative design evidence and does not contribute to design-specific or RoB-specific claims.
- 1 supporting study does not have a displayable topic-matched quantitative effect.
- Evidence uses heterogeneous comparison contexts: active_comparator, unknown_unresolved.
- 1 supporting study has high, serious, critical, unclear, or unavailable risk-of-bias information.
- 2 of 3 studies with duration data have follow-up of 12 weeks or less.
Supporting evidence
Inspect the authoritative studies and omitted support records for this dossier.